Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 2.7% Higher - Still a Buy?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report)'s stock price shot up 2.7% during trading on Friday . The company traded as high as $6.59 and last traded at $6.58. 3,679 shares traded hands during trading, a decline of 92% from the average session volume of 45,397 shares. The stock had previously closed at $6.41.Get Armata Pharmaceuticals alerts:Armata Pharmaceuticals Stock PerformanceThe firm has a market capitalization of $239.58 million, a P/E ratio of -4.06 and a beta of 1.24. The stock has a fifty day moving average price of $6.07 and a two-hundred day moving average price of $3.78. Institutional Trading of Armata PharmaceuticalsAn institutional investor recently bought a new position in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the SEC. 3.57% of the stock is currently owned by institutional investors and hedge funds. Armata Pharmaceuticals Company Profile (Get Free Report)Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings. Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.Further ReadingFive stocks we like better than Armata PharmaceuticalsDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Do you know what Amazon is planning for January 1?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Armata Pharmaceuticals Right Now?Before you consider Armata Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here